A non-systemic phosphodiesterase-5 inhibitor suppresses colon proliferation in mice

Avelina Lee¹, Iryna Lebedyeva¹, Wenbo Zhi¹, Vani Senthil¹, Herjot Cheema¹, MIchael Brands¹, Weston Bush¹, Nevin Lambert¹, Madeline Snipes¹, and Darren Browning¹

¹Augusta University

September 21, 2022

Abstract

Background and Purpose: Phosphodiesterase-5 inhibitors (PDE5i) are under investigation for repurposing as an intervention for colon cancer prevention. A drawback to conventional PDE5i are side-effects and drug-drug interactions that would be poorly tolerated when taken on a chronic basis for prevention. Experimental Approach: We designed an analog of the prototypical PDE5i sildenafil by replacing the methyl group on the piperazine ring with malonic acid to reduce lipophilicity and measured its entry into the circulation and effects on colon epithelium. Key Results: This modification did not affect pharmacology as malonyl-sildenafil had a similar IC50 to sildenafil (6.5 nM vs 7.5 nM respectively) but exhibited almost 100-fold reduced cell entry compared to sildenafil. Using an LC-MS/MS approach, doses of malonyl-sildenafil up to 36 mg/kg were barely detectable in mouse plasma after oral administration but was detected at high levels in the feces. This contrasted with sildenafil that was detected in the plasma but not in the feces. No bioactive metabolites of malonyl-sildenafil were detected in the circulation by measuring interactions with isosorbide mononitrate. Treatment of mice with malonyl-sildenafil in the drinking water for 8 days was well-tolerated and resulted in a suppression of proliferation in the colon epithelium that is consistent with results published previously for mice treated with PDE5i. Conclusion and Implications: A carboxylic acid-containing analog of sildenafil prohibits systemic delivery of the compound but maintains sufficient penetration into the colon epithelium to suppress proliferation. This highlights a novel approach to generate a first in class drug for colon cancer chemoprevention.

A non-systemic phosphodiesterase-5 inhibitor suppresses colon proliferation in mice.

Running title: A non-systemic PDE-5 inhibitor for colon cancer prevention

Authors and Affiliations:

Avelina Lee ¹, Iryna Lebedyeva ², Wenbo Zhi ³, Vani Senthil ¹, Herjot Cheema ¹, Mike Brands ⁴, Weston Bush⁴, Nevin Lambert ⁵, Madeline Snipes⁵, and Darren D. Browning ¹,⁶

¹ Department of Biochemistry and Molecular Biology, Augusta University, Augusta, GA
² Department of Chemistry and Physics, Augusta University, Augusta, GA
³ Center for Biotechnology and Genomic Medicine, Augusta University, Augusta, GA
⁴ Department of Physiology, Augusta University, Augusta, GA
⁵ Department of Pharmacology and Toxicology, Augusta University, Augusta, GA
⁶ Corresponding Author:

Georgia Cancer Center, CN 1167
1410 Laney Walker Blvd, Augusta, Georgia 30912-2100, USA
Availability of data: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Abstract

Background and Purpose. Phosphodiesterase-5 inhibitors (PDE5i) are under investigation for repurposing as an intervention for colon cancer prevention. A drawback to conventional PDE5i are side-effects and drug-drug interactions that would be poorly tolerated when taken on a chronic basis for prevention.

Experimental Approach. We designed an analog of the prototypical PDE5i sildenafil by replacing the methyl group on the piperazine ring with malonic acid to reduce lipophilicity and measured its entry into the circulation and effects on colon epithelium.

Key Results. This modification did not affect pharmacology as malonyl-sildenafil had a similar IC$_{50}$ to sildenafil (6.5 nM vs 7.5 nM respectively) but exhibited almost 20-fold reduced EC$_{50}$ for increasing cellular cGMP. Using an LC-MS/MS approach, doses of malonyl-sildenafil up to 36 mg/kg were barely detectable in mouse plasma after oral administration but was detected at high levels in the feces. This contrasted with sildenafil that was detected in the plasma but not in the feces. No bioactive metabolites of malonyl-sildenafil were detected in the circulation by measuring interactions with isosorbide mononitrate. Treatment of mice with malonyl-sildenafil in the drinking water for 8 days was well-tolerated and resulted in a suppression of proliferation in the colon epithelium that is consistent with results published previously for mice treated with PDE5i.

Conclusion and Implications. A carboxylic acid-containing analog of sildenafil prohibits systemic delivery of the compound but maintains sufficient penetration into the colon epithelium to suppress proliferation. This highlights a novel approach to generate a first in class drug for colon cancer chemoprevention.

Keywords: Phosphodiesterase, intestines, colon neoplasms

Bullet point summary:

What is already known
Phosphodiesterase 5 inhibitors have been highlighted as potentially valuable for preventing colorectal cancer in high-risk individuals.

Conventional phosphodiesterase 5 inhibitors enter the circulation to cause side-effects and drug-drug interactions that reduce their suitability as chemoprevention agents.

What this study adds
Adding a carboxylic acid group to the prototypical phosphodiesterase inhibitor sildenafil produces an analog that is gut-retained and does not enter the circulation in mice.

Malonyl-sildenafil is a carboxylic acid containing analog of sildenafil with low systemic delivery but is equally potent as sildenafil at suppressing proliferation in the colon epithelium of mice.

Clinical significance
Colorectal cancer is one of the most commonly diagnosed, but nothing has been approved for the chemoprevention in high-risk patients.

Polar analogs of conventional phosphodiesterase 5 inhibitors are attractive agents for colon cancer prevention because they are gut-targeted and are expected to have reduced side-effects and drug-drug interactions.

Introduction
Colorectal cancer (CRC) is one of the most commonly diagnosed and represents approximately 8% of all cancer deaths due to the late stage at diagnosis when treatments are ineffective. The primary prevention of
CRC is therefore very important for high-risk patients. The average lifetime risk for developing sporadic CRC is about 1 in 23, but there are millions at 3-5 fold higher risk, including those with recurrent polypectomy and those with first-person relatives with an early diagnosis (Roos et al., 2019). The typical recommendations for these high-risk patients include lifestyle modifications that have a marginal effect, and colonoscopy with polypectomy to detect and remove precancerous polyps (Oruc et al., 2019; Yao et al., 2017). Colonoscopy is the most effective approach to CRC prevention, but there are many cultural, geographic and economic barriers that limit the availability of this invasive procedure (Sachdev et al., 2019; Wagner et al., 2019; Zhao et al., 2019). Chemoprevention agents are needed for CRC, but apart from NSAIDs that have significant side effects (Veettil et al., 2017), nothing has been approved for this purpose.

A large body of preclinical evidence has highlighted the potential use of cGMP-elevating agents to prevent colon cancer (Islam et al., 2018). Uroguanylin and guanylin are peptide hormones that trigger intracellular cGMP production by activating epithelial guanylyl cyclase C receptors (GC-C) (Forte, 2004). In vivo studies using knockout mice with defective cGMP signaling have shown that cGMP controls intestinal homeostasis by slowing epithelial turnover (Li et al., 2007; Steinbrecher et al., 2002; Wang et al., 2012). GC-C knockout mice also exhibit increased tumorigenesis in both AOM and Apc<sup>Min/+</sup> mouse models of colon cancer (Li et al., 2007; Lin et al., 2010). Moreover, increasing cGMP in wild type mice using exogenous GC-C agonists inhibits tumorigenesis in Apc<sup>Min/+</sup> mice (Chang et al., 2017; Shailubhai et al., 2000; Sharman et al., 2018). Phosphodiesterase 5 is expressed in the intestinal epithelium, and antagonizes the effects of GC-C agonists by degrading cGMP (Bakre et al., 2000). Phosphodiesterase 5 inhibitors (PDE5i) such as sildenafil amplify the effect of endogenous GC-C agonists and suppress proliferation in the colon (Sharman et al., 2018; Sharman et al., 2017; Wang et al., 2014). Landmark studies showed that a clinically relevant dose of PDE5i can block tumorigenesis by 50% in both AOM/DSS and Apc<sup>Min/+</sup> mouse models of CRC (Islam et al., 2017; Sharman et al., 2018). Sildenafil reduced polyp multiplicity in these studies but did not affect the size of the initiated polyps, indicating that the central effect of cGMP is to suppress tumor initiation (Browning, 2019; Islam et al., 2018).

Two recent large cohort retrospective studies suggest that PDE5i might also prevent CRC in humans. The first report used the Swedish Hospital Discharge Register to show that polypectomy patients who had taken PDE5i had 36% less incidence of CRC compared to those who had never been exposed to PDE5i (Huang et al., 2019). The second report interrogated the Veterans Affairs Database, and found that patients taking PDE5i over the long term had up to 50% reduction in CRC incidence (Lilley et al., 2020). Prospective clinical studies are needed to support the repurposing PDE5i for CRC chemoprevention. Conventional PDE5i (e.g. sildenafil, tadalafil) that are most widely prescribed for erectile dysfunction, have also been safely used to treat chronic diseases including pulmonary arterial hypertension and benign prostate hyperplasia (Cohen et al., 2019; Hatzimouratidis, 2014). However, side effects of these drugs such as headache, flushing and dyspepsia, would be less tolerated by otherwise healthy patients using them to reduce their risk of CRC. Moreover, due to common predisposing factors, many high-risk CRC patients also take nitroglycerin to treat ischemic heart disease (Boden et al., 2015). Due to drug-drug interactions, these patients could not benefit from PDE5i for CRC prevention. PDE5i that avoid systemic delivery would therefore be a major advantage as an agent for CRC chemoprevention. The present study has designed an analog of sildenafil that exhibits poor membrane permeability, and we show that it avoids systemic delivery while retaining the anti-proliferative ability of PDE5i in the colon epithelium.

**Methods**

**Chemicals**

Malonyl-sildenafil was custom-synthesized by Leadgen Labs (Orange, CT) using desmethyl-sildenafil and malonic acid as building blocks. Desmethyl-sildenafil was purchased from Chemspace (Monmouth Junction, NJ). The sildenafil citrate (Revatio) and Linclotide (Linzess) were extracted from pharmacy-grade pill/capsule in water, and stored as aliquots at -80°C. The doxycycline, puromycin, G418, and isosorbide mononitrate were from Sigma Chemical (St. Louis MO) and all other chemicals and reagents were from Fisher Scientific (Waltham, MA).
Western blotting

Cells were lysed by incubation in ice-cold lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 0.25% deoxycholate) supplemented with protease and phosphatase inhibitor cocktail (Fisher Scientific, Waltham, MA). Clarified protein extracts were quantified using a BCA protein quantification kit (Fisher Scientific, Waltham, MA). Proteins were then separated on 10% polyacrylamide minigels (BioRad, Hercules CA), transferred to nitrocellulose membranes and blocked with 5% BSA in PBS containing 0.025% Tween 20. Antibodies used for immunoblotting: β-actin (1:2000, Sigma), PKG2 (mAb E7; 1:200, Santa Cruz Biotechnology), Antibodies against phospho-VASP (Ser239) and total VASP were from Cell Signaling (1:1000; Danvers, MA). Blots were visualized on film using Pierce-ECL substrate.

In vitro Pharmacology and permeability assays

The predicted LogS and LogD at different pH values for each structure were calculated using tools available at Chemicalize.com. The PDE-5 inhibitory activity of sildenafil and malonyl-sildenafil was measured in vitro using a commercially available kit according to the manufacturer instructions (BPS Bioscience, San Diego, CA). The assay was reproduced in three independent experiments with triplicate wells in each replicate. IC50 values were calculated using curve fitting functions in GraphPad Prism 9 (San Diego, CA).

The cell-based permeability assays were performed using LS-174T colon cancer cells obtained from the American Type Culture Collection. Cells were treated with 1 μM linaclotide together with different PDE5i concentrations for 4h, followed by processing of cell extracts for cellular cGMP measurement using cGMP ELISA kits according to the manufacturer instructions (Cayman Chemical). To assess activation of cGMP signaling by immunoblotting, we used LS174T cells with inducible PKG2 expression that were described recently (Hou et al., 2022).

Animal Studies

The goal of the studies described herein are to develop first-in-class agents for the chemoprevention of colorectal cancer in humans. Rodents are widely regarded as essential models for early pharmacology and toxicology studies, and mice were chosen owing to extensive published data demonstrating CRC chemoprevention by conventional PDE5i. For all animal studies, six-week-old C57BL6 mice were purchased from Jackson Laboratories (Bar Harbor, ME), and allowed to acclimate to the Augusta University animal facility for at least 2 weeks prior to experimentation. Mice were housed in shoebox cages with 5 mice of the same sex per cage with water and irradiated rodent chow (Teklad 8904) ad libitum. Cages were maintained in conventional specific pathogen free environment at 24°C, and a 12 h light/dark cycle. On completion of experiments or at any signs of morbidity, mice were euthanized by controlled CO2 delivery for humane asphyxiation followed by decapitation. The experimental design included equal numbers of randomly chosen male and female mice for the proof-of-principle pharmacokinetic studies, but only male mice were used for the surgical procedure and for the colon proliferation studies since our previous studies have found no difference in the response to cGMP elevation on colon homeostasis or colon cancer prevention. Statistical analysis was only undertaken for studies where each group size was at least n = 5. All studies carried out with animals were approved by the Augusta University Institutional Animal Care and Use Committee. Descriptions of animal studies are compliant with the ARRIVE guidelines (Percie du Sert et al., 2020) and recommendations made by the British Journal of Pharmacology (Lilley et al., 2020).

Pharmacokinetic studies

Mice were randomly caged in groups of 3 of each sex where each data point (dose or time) was derived from 6 mice. Stocks of sildenafil and malonyl-sildenafil were prepared in diH2O to deliver different doses by gavage of 0.1 ml per mouse, or 9 mg/kg for the time course. Blood was drawn from mice by submandibular bleed (Golde et al., 2005), and plasma was isolated using BD microtainer lithium tubes (Becton, Dickinson and Company, Franklin Lakes, NJ). Fecal pellets were collected over a 2 h period and the PDE5i were extracted by mixing with 1 ml methanol for 3 seconds in a Pro-200 homogenizer (Cole-Parmer, Vernon Hills, IL), followed by centrifugation at 10,000 x g for 10 min.
Arterial blood pressure measurements

Male C57BL/6J mice (n=4) were implanted with a PA-C10 blood pressure transmitter in the right carotid artery (Data Sciences International, St. Paul, MN), and after recovery from surgery the data was recorded using the DSI PhysioTel system (Data Sciences International, St. Paul, MN). For each experiment the mice were randomly selected for treatment with ISMN mixed in H2O and 0.1 ml was injected i.p. for a final dose of 300 mg/kg. This was followed by gavage of 0.1 ml of H2O (control), sildenafil, or malonyl-sildenafil at 10 mg/kg, and the mice were returned to the cage for monitoring. The experiment was repeated until each treatment had been reproduced in 5 independent biological trials after which mice were euthanized.

The surgical procedures and implantable telemetry approach for measuring blood pressure in mice have been described in detail previously (Lee et al., 2004). In brief, all surgical instruments were autoclaved on a stainless steel tray that was used as the sterile surface during surgery. The mouse is anesthetized in an isoflurane-inducing chamber. Anesthesia used a fitted nose cone connected to an isoflurane system running 2% in a stream of 100% oxygen mixed with room air. The incision area was shaved and prepped with betadine and rinsed with 70% ethanol. Anesthesia was assessed continuously during shaving and prepping for surgery, with appropriate adjustments. An approximately 10 mm incision was made in the ventral neck region over the trachea to expose the left carotid artery. A subcutaneous tunnel was made on the right side leading to the midsacral region where a sterile Data Sciences BP transmitter unit was inserted into a pocket, and the catheter tip from the unit was inserted into the carotid artery and secured in place with silk ties. The incision was closed in one layer with sterile, 5-0 or 6-0 silk suture. After closing the incision, the mouse was removed from anesthesia, buprenorphine SR was administered i.p. and the mouse is placed in a clean, warmed cage to recover. Once fully conscious and able to ambulate, mice were transferred to individual plastic shoe box cages and placed on top of Data Sciences receivers that have been matched to the respective transmitters. Approximately 5-7 days were allowed from surgical procedures before beginning experimental procedures and measurements.

Measuring cell proliferation in the colon epithelium

Mice (n=6, males) were provided sildenafil or malonyl-sildenafil ad libitum in the drinking water dissolved at a concentration that delivered 9 mg/kg daily. Mice were weighed daily, and after at least 5 days of continuous consumption they were sacrificed, and the colon was dissected and processed for quantitation of proliferation by flow cytometry (proximal region) and by IHC (distal region). For flow cytometry, the epithelium was enriched by isolating crypts as described previously (Islam et al., 2022), followed by ethanol fixation and staining with phycoerythrin-conjugated anti-mouse Ki-67 antibodies according to the manufacturer instructions (Biolegend, San Diego, CA). Flow cytometry was carried out using a BD Accuri C6 flow cytometer, and data was analyzed using FCS Express 7 software (De Novo Software, Pasadena, CA). Processing the distal colon tissues for histology and immunohistochemistry was carried out as previously described (Wang et al., 2012). Briefly, tissues were fixed with 10% formaldehyde, embedded in paraffin blocks, and sectioned by the Augusta University histology core. The tissues were probed using antibodies to PCNA (1:100; Cell Signaling, Danvers, MA). Visualization of PCNA antibodies was done using the ImmunoCruz ABC kit (Santa Cruz Biotechnology, Dallas, TX, USA). At least 10 different regions of colon containing approximately 8 crypts per region were counted for each mouse. For both the flow-cytometer and immunohistochemistry approaches, each group (control, sildenafil, malonyl-sildenafil) contained 5 mice (male) and the experiment was reproduced in 2 independent replicates.

LC-MS/MS analysis

Samples were prepared by adding 180 μl acetonitrile (containing 1 nM loperamide as internal standard) to 20 μl mouse plasma or fecal extract. Samples were vortexed for 5 minutes at room temperature and centrifuged at 16,000 x g for 10 minutes at 4°C. After transfer of the supernatant to a glass vial, 8μl was injected into a Thermo Hypersil C18 column (100 x 2.1mm, 1.9um) on a Shimadzu Nexera UHPLC system and the separation of compounds was performed using a gradient elution from 25% to 95% acetonitrile (with 0.1% formic acid) in 5 minutes at a flow rate of 0.2 ml/min and oven temperature of 50°C. The effluent was
ionized using positive ion electrospray on a Thermo TSQ Quantiva triple-quadrupole mass spectrometer. The integrated peak areas for these transitions were calculated for each sample using Skyline software (version 21.0, University of Washington).

Statistical Analysis

All data are expressed as mean ± SD, and individual data points are shown in all studies where statistical significance was tested (n ≥ 5). The group sizes (number of mice per group or independent experimental replicates) for each study are stated in the figure legends. Cell proliferation and blood pressure data were analyzed for significance using one-way ANOVA followed by Tukey’s multiple comparisons test comparing to the untreated control. The differences were considered to be significant when p < 0.05. All statistical analyses were carried out using GraphPad Prism 9 (San Diego, CA).

Results

A carboxylic acid containing analog of sildenafil (retains pharmacological activity but exhibits reduced cell entry).

The lipophilic design of conventional PDE5i’s such as sildenafil, tadalafil and vardenafil, enables entry into the circulation that is essential to reach the target tissues. To create a PDE5i with reduced systemic delivery, we sought to reduce the lipophilicity by adding groups that carry a charge at physiological pH. To accomplish this, we substituted malonate for the methyl group on the piperazine ring of the prototypical PDE5i sildenafil. This structure (malonyl-sildenafil) is predicted to exhibit much higher solubility and reduced membrane permeability at physiological pH values (Fig. 1A, B). An in vitro assay for PDE5i activity revealed an IC\textsubscript{50} of 6.5 nM for malonyl-sildenafil that is similar to the parent compound (7.5 nM), indicating that the modification did not deleteriously affect the pharmacology (Fig. 1C). We used a novel cell-based assay to assess the ability of the PDE5i to enter colon epithelial cells and activate cGMP signaling (Fig. 2A). These results showed that malonyl-sildenafil was 18-fold less potent at increasing cGMP levels in the cells than the parent compound based upon EC\textsubscript{50} (Fig. 2B). These observations were supported by a highly sensitive assay for activation of cGMP-dependent protein kinase (Fig. 2C).

Malonyl-sildenafil does not enter the circulation following oral administration in mice.

In order to determine the extent to which malonyl-sildenafil can enter the circulation, we developed an LC-MS/MS procedure to measure the compound in plasma (Fig. 3). The ion spectrum used for sildenafil is based upon a previous study (Drueke et al., 2019), and several common peaks were generated by malonyl-sildenafil including m/z at 283, 311 and 377. However, additional peaks were observed that are consistent with loss of the carboxylic group (m/z = 503), and loss of the whole malonyl-group to generate desmethyl-sildenafil (m/z = 461). One hour after oral administration of malonyl-sildenafil to mice at concentrations up to 36 mg/kg did not result in detectable levels in the plasma (Fig 4A). This contrasted with sildenafil that was detected in plasma at 250 nM and 3.5 μM after administering 9 and 36 mg/kg (respectively). Notably, sildenafil was not detected in the feces collected between 2-4 hours after oral administration, but malonyl-sildenafil was detected at high levels ranging from 90 μg/g to 244 μg/g after administering 9 and 36 mg/kg respectively (Fig. 4B). The decision to measure malonyl-sildenafil one hour following oral administration was based upon established pharmacokinetics for sildenafil (Nichols et al., 2002; Walker et al., 1999). The possibility that the reduced membrane permeability of malonyl-sildenafil could cause delayed entry into the circulation was tested by performing a time course using 9 mg/kg (Fig. 4C). Apart from a very small (11 nM) peak at 1 hour, these experiments revealed that there was no delayed peak, and malonyl-sildenafil was not detected in the plasma at any other time during the 24-hour period examined. Notably, malonyl-sildenafil continued to be excreted at high levels in the feces 8 hours after oral administration (Fig. 4D).

Consuming PDE5i together with soluble guanylate cyclase stimulators such as riociguat, or nitrate activators such as isosorbide mononitrate (ISMN) and nitroglycerin is contraindicated due to the risk of severe hypotension. Malonyl-sildenafil was not detected at high levels in the plasma compared to sildenafil, but bioactive metabolites could have been created that could enter the circulation undetected. To investigate
this possibility, mice were treated with ISMN (300 mg/kg i.p.) alone, or together with orally administered sildenafil or malonyl-sildenafil (10 mg/kg). Arterial blood pressure was then measured over time using remote telemetry (Fig. 5). ISMN alone or with malonyl-sildenafil slightly increased blood pressure from a baseline of around 100 mmHg to 126 mmHg and 117 mmHg (respectively). This was most likely due to stress caused by the procedure. As expected, co-administration of ISMN and sildenafil caused a rapid drop in blood pressure to 68 mmHg that returned to close to the baseline over the following 30 minutes.

Oral administration of malonyl-sildenafil suppresses proliferation in the colon epithelium.

The pharmacokinetic data support the idea that malonyl-sildenafil has reduced permeability and does not enter the circulation following oral administration in mice. It was therefore important to determine whether malonyl-sildenafil could enter the colon epithelium to suppress proliferation, which is thought to be the central effect of PDE5i that mediates colon cancer prevention (Browning, 2019; Islam et al., 2018). Mice were maintained on malonyl-sildenafil (9 mg/kg) in the drinking water for up to 8 days, and there was no difference in body weight compared to those on sildenafil or water alone (Fig. 6A). The initial drop in weight in the first couple of days most likely reflected a distaste for the compound since they initially drank less than the control groups. Mice were active and exhibited no observed deleterious effects during the time studied. Histological analysis of the colon mucosa after 8 days consuming malonyl-sildenafil revealed no obvious epithelial damage, edema, or leukocyte infiltration (Fig. 6B). Malonyl-sildenafil was not detected in the plasma of mice drinking malonyl-sildenafil for 8 days, but low levels of sildenafil (3.3 nM) were observed in the plasma of mice drinking sildenafil (Fig. 6C). To determine the effect of orally administered malonyl-sildenafil on proliferation, the epithelium from the proximal half of the colons was isolated and subjected to flow cytometry to detect the proliferative marker Ki67 (Fig. 7A, B). This showed a median of 23% Ki67+ cells in the control animals on drinking water alone, but this was significantly reduced to 11% and 7% by sildenafil and malonyl-sildenafil treatment (respectively). Sections of the distal colon were also stained for PCNA, which showed the expected proliferative compartment in the lower third of the crypts (Fig. 6C). Both sildenafil and malonyl-sildenafil reduced the number of PCNA+ cells/crypt by about 30% (Fig. 6D). Taken together these results demonstrate that orally administered malonyl-sildenafil and sildenafil were equally effective at suppressing proliferation in the colon epithelium of mice.

Discussion and Conclusions

Sildenafil epitomizes the hallmark Rule of 5 (Ro5) properties (Lipinski, 2004; Lipinski et al., 2001) regarding overall size and lack of polarity that allow near-complete systemic delivery into the circulation (Hong et al., 2017; Walker et al., 1999). Extensive structural studies of sildenafil have identified the piperazine nitrogen as amenable to modifications that affect pharmacokinetic properties without dramatically affecting pharmacological efficacy (Dunn, 2005; Kim et al., 2001b; Kim et al., 2001c; Yoo et al., 2007). To develop a non-systemic PDE5i we chose to replace the methyl group of sildenafil with malonate, which is predicted to dramatically reduce permeability at post-gastric pH values between 5-7. This modification did not affect the inhibitor potency as malonyl-sildenafil was equally potent as sildenafil toward human PDE5a. The IC50 value for sildenafil determined using the assay conditions in the present study were slightly higher than previously reported (Gupta et al., 2005). However, the results are congruent with a previous study suggesting that the carboxylate mimics the phosphate of cGMP to increase affinity (Kim et al., 2001a). We used a novel assay to assess cell permeability, whereby entry of PDE5i into colon cancer cells amplifies GC-C activity that is driven by a low level of the synthetic agonist linaclotide. We used ELISA to measure cGMP levels in our system, which demonstrated a dramatic reduction in EC50 for malonyl-sildenafil compared to the parent compound sildenafil. This observation was supported using activation of cGMP-dependent protein kinase (PKG2) as a readout for the ability of PDE5i to enter cells and increase cGMP levels. As the IC50 toward purified PDE5 was similar, these results support the idea that the carboxylic acid group impeded diffusion of malonyl-sildenafil across the plasma-membrane. However, a differential susceptibility of the compounds to efflux pumps (e.g., MDR1) might also have contributed to the exclusion but was not investigated here.

Sildenafil exhibits near-complete systemic delivery (Hong et al., 2017), and in circulation it undergoes hepatic modification into desmethyl-sildenafil that retains some bioactivity (Kim et al., 2003). The prominent
desmethyl-sildenafil peak in the MS/MS ion spectrum is due to the ionization energy as it was not detected in the liquid chromatography elution profile using pure compound, or in the plasma from malonyl-sildenafil treated mice (not shown). One of the most significant findings is that oral administration of malonyl-sildenafil even at concentrations up to 36 mg/kg exhibited minimal leakage into the circulation but was excreted at high levels in the feces. This contrasted sharply with sildenafil, which peaked at 1-2 hours in the plasma and was not detected in the feces. The typical human dose of sildenafil is 0.7-1.4 mg/kg that is equivalent to consumption of a 50 or 100 mg pill (respectively). The 36 mg/kg dose used here is 26 times the maximum human dose, and 2-4-fold the human dose with allometric scaling. This clearly demonstrates that malonyl-sildenafil has very poor permeability in vivo and is largely retained in the gut lumen. The typical transit time for these mice is between 2-4 hours (Sharman et al., 2017), so the continued excretion of malonyl-sildenafil in the feces 8 hours after oral gavage was surprising. One possibility for future exploration is that the drug is retained in the mucus layer long after excretion of the luminal contents. Regardless, this property is ostensibly ideal for a drug that targets the colon epithelium. A major drawback to the use of contemporary PDE5i for colon cancer prevention is the contraindication for patients taking nitrates to treat stable angina due to synergistic hypotensive effects (Lee et al., 2004). It was shown here that malonyl-sildenafil did not significantly affect blood pressure in mice exposed to ISMN. This supports the pharmacokinetic data and is congruent with the notion that bioactive lipophilic metabolites were not generated from malonyl-sildenafil.

Taken together the pharmacokinetic results demonstrated that malonyl-sildenafil did not enter the circulation, but it was unclear whether it could target the colon epithelium. Previous studies have demonstrated that PDE5i treatment of mice can alter intestinal homeostasis by suppressing proliferation and apoptosis while promoting differentiation (Sharman et al., 2017; Wang et al., 2014). The suppression of proliferation in the preneoplastic epithelium has been proposed to mediate the CRC-prevention effects of PDE5i (Browning, 2019; Islam et al., 2018) because this proliferative compartment is where replication errors and genotoxic stress drive neoplastic transformation (Chamorro-Jorganes et al., 2010; Tomasetti et al., 2017). Two different approaches were used to demonstrate that oral administration of malonyl-sildenafil to mice was equally effective as sildenafil at suppressing the proliferative compartment in the colon. This result was surprising because the 18-fold reduction in cell penetration for malonyl-sildenafil (EC50) would predict a lesser response in vivo. It is plausible that malonyl-sildenafil levels became concentrated in the mucosal region over time. However, a more plausible explanation is that the lengthy exposure of malonyl-sildenafil to the colon epithelium compared to transient delivery of sildenafil by systemic delivery through the vasculature, produced a larger area under the curve to compensate. These possibilities might be explored in future studies with this compound.

In summary, with the goal of creating a non-systemic PDE5i that targets the colon epithelium, we have synthesized a novel analog of sildenafil containing a carboxylic acid group derived from malonic acid. Malonyl-sildenafil remains in the colon for many hours without entering the circulation and is equally effective as sildenafil at suppressing epithelial proliferation. The results shown here are proof of principle that will enable the development of drugs for the prevention and treatment of intestinal disorders, with fewer side-effects and drug-drug interactions.

Acknowledgement: This work was supported by a grant from the Georgia Research Alliance, USA (GRA.VL21.E1 to DDB), and from the National Institutes of Health (1 R15 CA264555-01 to IL).

Conflict of interest statement: DDB and IL are cofounders of a startup biotechnology company (Targut Biotechnologies Inc.) that has the goal of developing drugs to target intestinal diseases.

References


**Figure Legends**

**Figure 1.** Malonyl-sildenafil is a polar analog with predicted low permeability. (A) Sildenafil is largely hydrophobic and exhibits poor solubility (LogS, circles) and high permeability (LogD, squares) at physiological pH. (B) Substitution of the piperazine methyl group in sildenafil with malonic acid is predicted to increase solubility and reduce permeability at physiological pH. The substitution is indicated by a dashed circle. LogS values from -2 to -4 are poorly soluble, and LogD values 0 to 5 are permeable. (C) *In vitro* assay for PDE5 inhibitory activity of sildenafil and malonyl-sildenafil. Data shown are mean +/- SD (n=3).

**Figure 2.** Malonyl-sildenafil retains pharmacological activity but exhibits poor membrane permeability. (A) Cartoon depicting an LS-174T-II cell-based assay where movement of the PDE5 inhibitor (PDE5i) across the plasma-membrane (dashed line) leads to increased cGMP in colon cancer cells treated with a low dose of linaclotide to stimulate guanylate cyclase-C (GC-C). Increased cGMP levels activate cGMP-dependent protein kinase (PKG) that phosphorylates vasodilator stimulated phosphoprotein (VASP). (C) The LS174T-II system (as depicted above) was treated with increasing doses of sildenafil or malonyl-sildenafil, and VASP phosphorylated on Ser239 (VASP-P) was determined by immunoblotting. Total VASP (VASP-t), and β-actin are loading controls, whereas PKG2 indicates equal expression of ectopic PKG2. Data in panel A are mean +/- SD (n=4), and results in panel C are representative of 3 independent experiments.

**Figure 3.** MS/MS Spectra for sildenafil and malonyl-sildenafil. Ion fragment patterns for Sildenafil (A) and Malonyl-sildenafil (B) . Proposed peak identification is illustrated by the dashed lines on the inset structure diagrams. The enlarged bold text indicates common ion peaks between the two compounds, and the asterisk marks the parent compound. The underlined peaks in panel B indicate unique ions generated by the malonyl group.

**Figure 4.** Pharmacokinetic analysis of malonyl-sildenafil in mice. Increasing doses of Malonyl-sildenafil (circles) or Sildenafil (squares) were administered to mice by gavage. LC-MS/MS was used to
measure the compounds in plasma after 1 hour (A), or in feces collected between 2-4 hours (B). The compounds were also measured at different time points after administration of a single 9 mg/kg dose in plasma (C) and feces (D). Data are mean +/- SD (n=6).

**Figure 5. Malonyl-sildenafil does not interact with isosorbide mononitrate in mice.** Mice were implanted with a carotid artery blood pressure transmitter (Data Science, PA-C10) and real time telemetry was recorded with a DSI PhysioTel system. Mice were randomly administered isosorbide mononitrate by i.p. injection (ISMN; 300 mg/kg) with orally administered vehicle, sildenafil or malonyl-sildenafil (10 mg/kg) as indicated. (A) Blood pressure recording with inset key showing when the drugs were administered. (B) Mean pressure (3 min) before drug (Pre) and after drug (post). Data are mean +/- SD (n=5), and p values are from ANOVA with Tukey’s multiple comparisons test.

**Figure 6. Malonyl-sildenafil is well-tolerated in mice.** Mice were maintained on water alone (Control), sildenafil (Sild) or malonyl-sildenafil (Mal) dissolved in the drinking water for up to 8 days as indicated. (A) Body mass measurements, (B) representative H&E-stained sections of the distal colon, scale bar is 30 μ. (C) Detection of Sild or Mal in the plasma at 8 days. Data are mean +/- SD (n=5).

**Figure 7. Malonyl-sildenafil suppresses proliferation in the colon epithelium of mice.** Mice were treated with 9 mg/kg sildenafil (Sild) or malonyl-sildenafil (Mal) in the drinking water, or with water alone (Ctrl). (A) After 8 days the proximal colon epithelium was harvested and subjected to flow cytometry measurement of Ki67+ cells. (B) Quantitation of treatment effects on Ki67+ cells. (C)PCNA+ cells in the distal colon were visualized by IHC, the scale bar is 30 μ. (D) Quantitation of treatment effects on PCNA+ cells per crypt. The plots in panels B and D show mean +/- SD, and p values are from one-way ANOVA followed by Tukey’s multiple comparisons test.
Figure 1
Figure 2

A) The signaling pathway involving GC-C, PDE5i, and PDE-5.

B) Graph showing the effect of different PDE-5i concentrations on cGMP levels. EC50 values: Sildenafil (0.67 µM), Malonyl-Sildenafil (12.1 µM).

C) Western blot analysis of VASP-P, VASP-t, PKG2, and b-actin expression at various drug concentrations for Sildenafil and Malonyl-Sildenafil.
Figure 3
Figure 5

A

Arterial Blood pressure (mmHg)

Time (minutes)

Pre Post

Drug

ISMN+Mal
ISMN+Sild
ISMN

B

Blood Pressure (mm Hg)

Pre Post

p=0.0048

p=0.9193

p=0.0048

p=0.9193
Figure 6
Figure 7

A. Graph showing the cell count distribution with Ctrl and Mal indicated.

B. Bar chart showing Ki67 positive cells (%) with Ctrl, Sild, and Mal treatments.

C. Images of PCNA staining for Ctrl, Sild, and Mal conditions.

D. Bar chart showing PCNA+ cells/crypt with Ctrl, Sild, and Mal treatments.

Statistical significance:
- $p=0.038$
- $p=0.0009$
- $p=0.3$
- $p<0.0001$